The rush to boost NAD+ precursors feels like trying to save a sinking ship by constantly bailing water, while ignoring the iceberg-shaped hole below the waterline. The reductionist logic is seductive: low NAD+ correlates with dysfunction, so raise it. But systems biology asks a harder question—what is the system optimizing for by lowering NAD+?

We have data showing NAD+ decline isn't passive degradation; it's a programmed metabolic shift. In many models, it coincides with the downregulation of repair pathways and the upregulation of survival mechanisms. Forcing NAD+ back to youthful levels with NMN or NR might, in some contexts, be like overriding a critical system checkpoint. Are we inadvertently re-activating pathways the organism has deliberately silenced to, say, limit oncogenic potential or conserve energy for immediate survival?

Look at the work on the JNK-AP-1 threshold. Stress signaling that becomes chronic with age re-wires the transcriptional landscape. NAD+-dependent sirtuins are deeply embedded in this network. Artificially propping up one node (SIRT1/3 activity) might destabilize an entire signaling equilibrium that's evolved to manage trade-offs between growth, repair, and senescence. The short-term biomarker improvements could mask long-term network incoherence.

This isn't an argument against NAD+ research—it's a plea for systems-level auditing. We need studies that track the secondary and tertiary effects of sustained NAD+ boosting on integrated physiology: the epigenome, the proteostasis network, immune surveillance, and importantly, cellular decision-making at the senescence-apoptosis interface. Does it alter the quality of senescent cells, making them more or less pathological? Does it affect the fidelity of reprogramming?

The field's biggest risk is a therapeutic reductionist blind spot. Aging is an emergent property of a complex system. We need collaborators in network theory, dynamical systems, and even ecology to model these trade-offs. Funding should prioritize longitudinal, multi-omic interventions in whole organisms over quick biomarker wins. We might be looking at a master regulator, or we might be looking at a downstream passenger. Either way, we need to see the whole board, not just one piece.

The question isn't if we can raise NAD+. It's what system we're destabilizing to do it.